SCHEMBL24090141

SCHEMBL24090141

CS(=O)(=O)c1ccc2nc(Nc3ccccc3)n(-c3ccccc3)c(=O)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.43
▸ KDM1A O60341 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ PLA2G1B P04054 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ ATG4B Q9Y4P1 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ PDE4B Q07343 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ TOP2B Q02880 1/20 0.39
▸ TRPV4 Q9HBA0 1/20 0.39
▸ PI4KA P42356 1/20 0.39
▸ PIK3CG P48736 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24090004 0.88 TDO2 (0.45) KDM1API4KAPIK3CGPTGS2
SCHEMBL29623407 0.86 RIPK2 (0.44) GAACA9
SCHEMBL23045334 0.80 TDO2 (0.50) USP2MAPTPIK3CG
SCHEMBL29623155 0.80 TDO2 (0.50) USP2MAPTPIK3CG
SCHEMBL24089978 0.80 TUBB4A (0.48) USP2KDM4ELMNAHTT
SCHEMBL24090148 0.80 HSD17B10 (0.45) USP2KDM1AMAPT
SCHEMBL23065106 0.80 SMN1; SMN2 (0.50) USP2ALDH1A1LMNACA2CA9
SCHEMBL24090104 0.80 USP2 (0.44) USP2MAPTPDE4B
SCHEMBL24111053 0.79 PDE4B (0.47) ALDH1A1KDM4ELMNAMAPTPDE4B
SCHEMBL24089901 0.77 G6PD (0.44) USP2ALDH1A1GAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 — — US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 — — US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL USP2 3443/4885KDM1A 1398/4885ALDH1A1 645/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 USP2 3548/4885KDM1A 1575/4885ALDH1A1 739/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 USP2 3548/4885KDM1A 1575/4885ALDH1A1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback